|
SG128680A1
(en)
|
2003-07-22 |
2007-01-30 |
Crucell Holland Bv |
Binding molecules against sars-coronavirus and uses thereof
|
|
CA2548942C
(en)
*
|
2003-12-05 |
2013-10-15 |
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health |
Anti-sars monoclonal antibodies
|
|
US8106170B2
(en)
|
2004-11-11 |
2012-01-31 |
Crucell Holland B.V. |
Compositions against SARS-coronavirus and uses thereof
|
|
AU2005304624B2
(en)
|
2004-11-12 |
2010-10-07 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
HRP20150279T1
(hr)
|
2007-12-26 |
2015-05-08 |
Xencor, Inc. |
Fc inaäśice s promijenjenim vezanjem na fcrn
|
|
UA119328C2
(uk)
|
2013-08-09 |
2019-06-10 |
Астеллас Фарма Інк. |
Антитіло до тslp-рецептора людини
|
|
CN108064243B
(zh)
|
2014-10-01 |
2021-08-27 |
免疫医疗有限公司 |
对lox1具有特异性的结合蛋白及其用途
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
WO2020180398A1
(en)
|
2019-01-14 |
2020-09-10 |
The Regents Of The University Of California |
Compositions and methods for modulating cellular internalization
|
|
AR120698A1
(es)
|
2019-12-09 |
2022-03-09 |
Ablynx Nv |
Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
|
|
JP2023512684A
(ja)
|
2020-02-03 |
2023-03-28 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
|
|
WO2021156490A2
(en)
|
2020-02-06 |
2021-08-12 |
Vib Vzw |
Corona virus binders
|
|
BR112022017048A2
(pt)
|
2020-02-26 |
2022-11-16 |
Vir Biotechnology Inc |
Anticorpos contra sars-cov-2 e métodos para usar os mesmos
|
|
EP4121454A1
(en)
|
2020-03-19 |
2023-01-25 |
Imperial College Innovations Limited |
Coronavirus antibody
|
|
US11028167B1
(en)
*
|
2020-03-23 |
2021-06-08 |
Centivax, Inc. |
Anti-SARS-Cov-2 antibodies derived from 3bgf
|
|
KR20250107297A
(ko)
|
2020-04-02 |
2025-07-11 |
리제너론 파아마슈티컬스, 인크. |
항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
|
|
WO2021203053A1
(en)
|
2020-04-03 |
2021-10-07 |
Vir Biotechnology, Inc. |
Immunotherapy targeting a conserved region in sars coronaviruses
|
|
US20230348571A1
(en)
|
2020-04-06 |
2023-11-02 |
Vanderbilt University |
Cross-reactive coronavirus antibodies and uses thereof
|
|
JP2023521418A
(ja)
|
2020-04-10 |
2023-05-24 |
インビビド， インコーポレイテッド |
コロナウイルスｓタンパク質に特異的な化合物及びその使用
|
|
US20240059757A1
(en)
|
2020-04-14 |
2024-02-22 |
Vir Biotechnology, Inc. |
Antibodies against sars-cov-2 and methods of using the same
|
|
US20230174628A1
(en)
|
2020-04-28 |
2023-06-08 |
Peking University |
Anti-novel coronavirus monoclonal antibody and application thereof
|
|
WO2021226560A1
(en)
|
2020-05-08 |
2021-11-11 |
Vir Biotechnology, Inc. |
Antibodies against sars-cov-2
|
|
WO2021247925A1
(en)
|
2020-06-03 |
2021-12-09 |
Vir Biotechnology, Inc. |
Structure-guided immunotherapy against sars-cov-2
|
|
WO2022010912A1
(en)
|
2020-07-06 |
2022-01-13 |
Flagship Pioneering Innovations Vi, Llc |
Antigen binding molecules targeting sars-cov-2
|
|
CA3183367A1
(en)
|
2020-07-06 |
2022-01-13 |
Gevorg GRIGORYAN |
Antigen binding molecules targeting sars-cov-2
|
|
WO2022015573A2
(en)
|
2020-07-13 |
2022-01-20 |
President And Fellows Of Harvard College |
Sars-cov-2 antigen-binding proteins and uses thereof
|
|
WO2022026475A2
(en)
|
2020-07-27 |
2022-02-03 |
Igm Biosciences, Inc. |
Multimeric coronavirus binding molecules and uses thereof
|
|
WO2022046888A1
(en)
|
2020-08-25 |
2022-03-03 |
Target Discovery Merger Sub II, LLC |
Sars-cov-2 associated antibody compositions and methods of use
|
|
CN116528897A
(zh)
|
2020-08-26 |
2023-08-01 |
旗舰开拓创新六世公司 |
靶向SARS-CoV-2的抗原结合分子
|
|
KR20230127305A
(ko)
|
2020-12-29 |
2023-08-31 |
발-첨, 리미티드 파트너십 |
Covid-19에 대한 중화 단일클론 항체
|
|
WO2022159685A2
(en)
|
2021-01-22 |
2022-07-28 |
Vanderbilt University |
Sars-cov-2 coronavirus antibodies and uses thereof
|
|
WO2022204202A1
(en)
|
2021-03-23 |
2022-09-29 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
KR20240035758A
(ko)
|
2021-05-24 |
2024-03-18 |
비르 바이오테크놀로지, 인코포레이티드 |
조작된 폴리펩타이드
|
|
WO2022271863A1
(en)
|
2021-06-23 |
2022-12-29 |
Chan Zuckerberg Biohub, Inc. |
Coronavirus neutralizing compositions and associated methods
|
|
WO2023028603A2
(en)
|
2021-08-27 |
2023-03-02 |
Humabs Biomed Sa |
Engineered compositions
|
|
EP4147716A1
(en)
|
2021-09-10 |
2023-03-15 |
Samatva Research Corporation |
Anti-virus moiety immobilised in a matrix
|
|
EP4519310A1
(en)
|
2022-05-06 |
2025-03-12 |
Generate Biomedicines, Inc. |
Antigen binding molecules targeting sars-cov-2
|